ReviewJournal of the advanced practitioner in oncology

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL.

Nicholas Forcello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.